StockDuty ← Dashboard Sep 01, 2026 12:36 PM ET
CatalystFDA/Bio

Upstream Bio Announces Pivotal Phase 3 Development Plans for Verekitug in Both Severe Asthma and CRSwNP

Pivotal Phase 3 plans for verekitug target two indications, signaling major clinical advancement.

What changed
Why it matters
Pivotal Phase 3 plans for verekitug target two indications, signaling major clinical advancement.
Sources
eodhd
Related signals
PHASE 1 OF INDIA - US TRADE PACT HINGES ON SECTION 301 PROBE , OFFICIAL SAYS →PITNEY BOWES OUTLINES PHASE 2 STRATEGIC REVIEW WHILE PUSHING NEAREST DEBT MATURITY TO MARCH 2029 - SEEKINGALPHA →UNICYCIVE PLUMMETS FOLLOWING SECOND CRL FOR OLC FOR HYPERPHOSPHATEMIA - SEEKINGALPHA →